Skip to main content

Lung Cancer

Conference Highlights ASCO, Lung Cancer

Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC

Phoebe Starr

COVID-19, Lung Cancer

Patients with Lung Cancer Distressed About Impact of COVID-19 on Access to Care

Walter Alexander

EGFR Most Common Mutation in Women with Lung Cancer and No Smoking History

Walter Alexander

FDA Approvals, Lung Cancer

Tagrisso Approved as Adjuvant Therapy for NSCLC with EGFR Mutations

Adjuvant Osimertinib a Practice-Changing Treatment in Early-Stage NSCLC with EGFR Mutation

Wayne Kuznar

Durvalumab plus Chemotherapy New Standard of Care for Extensive-Stage Small-Cell Lung Cancer

Phoebe Starr

Capmatinib Shows Activity in MET-Amplified Non–Small-Cell Lung Cancer

Wayne Kuznar

FDA Approvals, Lung Cancer, Select Drug Profiles

FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation

FDA Approvals, Lung Cancer, Select Drug Profiles

Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression

FDA Approvals, Lung Cancer, Select Drug Profiles

Tecentriq plus Avastin First Immunotherapy Regimen Approved for Metastatic Hepatocellular Carcinoma

1
2
3
4

Page 1 of 5
Results 1 - 10 of 44